LSV Asset Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $95.9M | Buy |
444,049
+110,310
| +33% | +$21.1M | 0.17% | 172 |
|
|
2026
Q1 | $61.2M | Buy |
333,739
+16,924
| +5% | +$3.12M | 0.13% | 199 |
|
|
2025
Q4 | $55.8M | Buy |
316,815
+9,976
| +3% | +$1.63M | 0.12% | 203 |
|
|
2025
Q3 | $43M | Buy |
306,839
+54,880
| +22% | +$7.42M | 0.09% | 223 |
|
|
2025
Q2 | $31.6M | Buy |
251,959
+9,983
| +4% | +$1.24M | 0.07% | 249 |
|
|
2025
Q1 | $33.1M | Buy |
241,976
+7,528
| +3% | +$1.08M | 0.08% | 246 |
|
|
2024
Q4 | $35.9M | Buy |
234,448
+192,948
| +465% | +$32.5M | 0.08% | 242 |
|
|
2024
Q3 | $8.04M | Buy |
+41,500
| New | +$8.68M | 0.02% | 447 |
|
|
2024
Q1 | – | Sell |
-117,030
| Closed | -$30.3M | – | 862 |
|
|
2023
Q4 | $30.3M | Sell |
117,030
-227,622
| -66% | -$55.9M | 0.07% | 281 |
|
|
2023
Q3 | $88.6M | Sell |
344,652
-8,772
| -2% | -$2.35M | 0.21% | 149 |
|
|
2023
Q2 | $101M | Sell |
353,424
-13,030
| -4% | -$3.88M | 0.22% | 141 |
|
|
2023
Q1 | $102M | Buy |
366,454
+7,600
| +2% | +$2.1M | 0.23% | 135 |
|
|
2022
Q4 | $99.4M | Sell |
358,854
-10,268
| -3% | -$2.9M | 0.22% | 143 |
|
|
2022
Q3 | $98.6M | Sell |
369,122
-1,330
| -0.4% | -$282K | 0.23% | 132 |
|
|
2022
Q2 | $75.5M | Sell |
370,452
-3,198
| -0.9% | -$654K | 0.16% | 163 |
|
|
2022
Q1 | $78.7M | Buy |
373,650
+18,628
| +5% | +$4.05M | 0.14% | 178 |
|
|
2021
Q4 | $85.2M | Sell |
355,022
-6,580
| -2% | -$1.69M | 0.15% | 175 |
|
|
2021
Q3 | $102M | Buy |
361,602
+1,432
| +0.4% | +$469K | 0.19% | 154 |
|
|
2021
Q2 | $125M | Sell |
360,170
-557,961
| -61% | -$169M | 0.21% | 148 |
|
|
2021
Q1 | $257M | Sell |
918,131
-20,210
| -2% | -$5.45M | 0.44% | 68 |
|
|
2020
Q4 | $230M | Sell |
938,341
-50,751
| -5% | -$13.1M | 0.42% | 70 |
|
|
2020
Q3 | $281M | Sell |
989,092
-18,666
| -2% | -$5.21M | 0.57% | 42 |
|
|
2020
Q2 | $270M | Sell |
1,007,758
-67,119
| -6% | -$20.2M | 0.56% | 44 |
|
|
2020
Q1 | $340M | Sell |
1,074,877
-44,956
| -4% | -$13.6M | 0.82% | 27 |
|
|
2019
Q4 | $332M | Buy |
1,119,833
+1,869
| +0.2% | +$519K | 0.52% | 49 |
|
|
2019
Q3 | $260M | Buy |
1,117,964
+50,220
| +5% | +$11.7M | 0.43% | 67 |
|
|
2019
Q2 | $250M | Buy |
1,067,744
+144,830
| +16% | +$33.4M | 0.4% | 74 |
|
|
2019
Q1 | $218M | Buy |
922,914
+142,412
| +18% | +$44.8M | 0.35% | 81 |
|
|
2018
Q4 | $235M | Buy |
780,502
+21,391
| +3% | +$6.83M | 0.42% | 65 |
|
|
2018
Q3 | $268M | Buy |
759,111
+168,183
| +28% | +$57.9M | 0.4% | 69 |
|
|
2018
Q2 | $172M | Buy |
590,928
+28,269
| +5% | +$7.95M | 0.27% | 101 |
|
|
2018
Q1 | $154M | Buy |
562,659
+69,220
| +14% | +$21.5M | 0.24% | 120 |
|
|
2017
Q4 | $157M | Buy |
493,439
+7,705
| +2% | +$2.47M | 0.25% | 118 |
|
|
2017
Q3 | $152M | Buy |
485,734
+40,195
| +9% | +$11.9M | 0.25% | 119 |
|
|
2017
Q2 | $121M | Buy |
445,539
+411,170
| +1,196% | +$109M | 0.22% | 129 |
|
|
2017
Q1 | $9.4M | Buy |
34,369
+3,300
| +11% | +$933K | 0.02% | 471 |
|
|
2016
Q4 | $8.81M | Buy |
31,069
+4,949
| +19% | +$1.47M | 0.02% | 484 |
|
|
2016
Q3 | $8.18M | Buy |
26,120
+4,900
| +23% | +$1.45M | 0.02% | 463 |
|
|
2016
Q2 | $5.13M | Buy |
21,220
+11,000
| +108% | +$2.9M | 0.01% | 523 |
|
|
2016
Q1 | $2.66M | Buy |
+10,220
| New | +$2.7M | 0.01% | 618 |
|
|
2013
Q4 | – | Sell |
-740
| Closed | -$178K | – | 889 |
|
|
2013
Q3 | $178K | Buy |
+740
| New | +$166K | ﹤0.01% | 856 |
|
Other funds holding BIIB
AIM
LSV Asset Management's BIIB Position: Q2 2026 in Review
LSV Asset Management increased its Biogen (BIIB) stake by 33% in Q2 2026, buying an estimated $21.1M and bringing the position to 444,049 shares worth $95.9M. The position accounts for 0.17% of the portfolio, ranked #172.
LSV Asset Management first reported a position in BIIB in Q3 2013 and has held it in 41 quarters since. The position peaked at $340M in Q1 2020. 621 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- LSV Asset Management held 444,049 shares of Biogen worth $95.9M as of Q2 2026.
- LSV Asset Management bought 110,310 Biogen shares in Q2 2026, an estimated $21.1M.
- Biogen made up 0.17% of LSV Asset Management's portfolio in Q2 2026, its #172 holding.
- LSV Asset Management first reported a position in Biogen in Q3 2013 and has held it in 41 quarters since.
- LSV Asset Management's Biogen position peaked at $340M in Q1 2020.
- 621 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on LSV Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.